Celldex Therapeutics Company Profile (NASDAQ:CLDX)

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CLDX
  • CUSIP: 15117B10
  • Web: www.celldextherapeutics.com
Capitalization:
  • Market Cap: $382.82 million
  • Outstanding Shares: 125,104,000
Average Prices:
  • 50 Day Moving Avg: $3.20
  • 200 Day Moving Avg: $3.53
  • 52 Week Range: $2.85 - $5.13
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.97
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.02 million
  • Price / Sales: 54.53
  • Book Value: $2.00 per share
  • Price / Book: 1.53
Profitability:
  • EBIDTA: ($119,750,000.00)
  • Net Margins: -1,923.41%
  • Return on Equity: -51.46%
  • Return on Assets: -44.35%
Debt:
  • Current Ratio: 11.26%
  • Quick Ratio: 11.26%
Misc:
  • Average Volume: 1.81 million shs.
  • Beta: 2.67
  • Short Ratio: 9.93
 

Frequently Asked Questions for Celldex Therapeutics (NASDAQ:CLDX)

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.00. The company had revenue of $1.53 million for the quarter, compared to analysts' expectations of $0.57 million. Celldex Therapeutics had a negative net margin of 1,923.41% and a negative return on equity of 51.46%. View Celldex Therapeutics' Earnings History.

Where is Celldex Therapeutics' stock going? Where will Celldex Therapeutics' stock price be in 2017?

8 equities research analysts have issued 12-month price objectives for Celldex Therapeutics' shares. Their forecasts range from $3.00 to $16.00. On average, they anticipate Celldex Therapeutics' stock price to reach $8.07 in the next twelve months. View Analyst Ratings for Celldex Therapeutics.

What are analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

  • 1. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)
  • 2. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer. We are encouraged by Celldex’s partnership agreements with big players like Bristol-Myers and Roche. The recent Kolltan acquisition should bode well for the company. Celldex has a positive record of earnings surprises in the recent quarters. The company’s loss estimates have narrowed ahead its Q4 release.  However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid- stage nature of its pipeline. Any development or regulatory setback would weigh heavily on the stock. Celldex’s shares have seen a sharper decline than the industry in the past one year." (1/17/2017)

Are investors shorting Celldex Therapeutics?

Celldex Therapeutics saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 19,288,811 shares, an increase of 7.9% from the April 13th total of 17,875,300 shares. Based on an average daily volume of 1,356,420 shares, the days-to-cover ratio is presently 14.2 days. Currently, 15.5% of the company's shares are sold short.

Who are some of Celldex Therapeutics' key competitors?

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:

  • Larry Ellberger, Independent Chairman of the Board
  • Anthony S. Marucci, President, Chief Executive Officer, Director
  • Avery W. Catlin CPA, Chief Financial Officer, Senior Vice President, Secretary
  • Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer
  • Thomas Andrew Davis M.D., Executive Vice President and Chief Medical Officer
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Theresa M. LaVallee Ph.D., Senior Vice President - Regulatory and Precision Medicine
  • Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer`
  • James J. Marino Esq., Director

Who owns Celldex Therapeutics stock?

Celldex Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (0.00%), Vanguard Group Inc. (0.00%), KLP Enterprises LLC (0.00%), Columbia Wanger Asset Management LLC (0.00%), State Street Corp (3.67%) and Meditor Group Ltd (3.36%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Avery W Catlin, Larry Ellberger and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.

Who sold Celldex Therapeutics stock? Who is selling Celldex Therapeutics stock?

Celldex Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Columbia Wanger Asset Management LLC, UBS Group AG, JPMorgan Chase & Co., Highbridge Capital Management LLC, Russell Investments Group Ltd. and Frontier Capital Management Co. LLC. View Insider Buying and Selling for Celldex Therapeutics.

Who bought Celldex Therapeutics stock? Who is buying Celldex Therapeutics stock?

Celldex Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Vanguard Group Inc., Renaissance Technologies LLC, State of Wisconsin Investment Board, Dimensional Fund Advisors LP, AXA, State Street Corp and TSP Capital Management Group LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Larry Ellberger and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.

How do I buy Celldex Therapeutics stock?

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of Celldex Therapeutics stock can currently be purchased for approximately $3.06.


MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  342
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $8.07 (163.77% upside)

Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Jefferies Group LLCReiterated RatingHold$4.00 -> $3.50HighView Rating Details
3/21/2017AegisReiterated RatingBuyLowView Rating Details
3/15/2017HC WainwrightReiterated RatingBuy$6.00MediumView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$7.00N/AView Rating Details
11/8/2016WedbushReiterated RatingNeutral$3.00N/AView Rating Details
11/8/2016Cantor FitzgeraldReiterated RatingBuy$9.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
6/7/2016Cowen and CompanyReiterated RatingOutperform$12.00N/AView Rating Details
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00N/AView Rating Details
3/7/2016Oppenheimer Holdings Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/7/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
6/1/2015WBB SecuritiesReiterated RatingBuy$30.00 -> $40.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Celldex Therapeutics (NASDAQ:CLDX)
Earnings by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Earnings History by Quarter for Celldex Therapeutics (NASDAQ CLDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.29)($0.28)$0.57 million$1.53 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.34)($0.30)$1.10 million$1.87 millionViewListenView Earnings Details
11/7/2016Q3 2016($0.33)($0.29)$1.09 million$2.20 millionViewN/AView Earnings Details
8/8/2016Q2($0.34)($0.32)$0.96 million$1.39 millionViewListenView Earnings Details
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details
11/5/2015Q3($0.35)($0.32)$1.02 million$1.03 millionViewN/AView Earnings Details
8/10/2015Q215($0.34)($0.33)$0.51 million$2.18 millionViewListenView Earnings Details
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details
11/4/2014Q3($0.33)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.31)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.26)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celldex Therapeutics (NASDAQ:CLDX)
2017 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.30)($0.26)($0.28)
Q2 20173($0.27)($0.23)($0.26)
Q3 20173($0.28)($0.20)($0.24)
Q4 20173($0.29)($0.20)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celldex Therapeutics (NASDAQ:CLDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celldex Therapeutics (NASDAQ:CLDX)
Insider Ownership Percentage: 4.20%
Institutional Ownership Percentage: 55.99%
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2016Tibor KelerVPBuy3,000$3.32$9,960.00View SEC Filing  
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.00View SEC Filing  
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.00View SEC Filing  
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.00View SEC Filing  
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.00View SEC Filing  
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View SEC Filing  
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celldex Therapeutics (NASDAQ:CLDX)
Latest Headlines for Celldex Therapeutics (NASDAQ:CLDX)
Source:
DateHeadline
nasdaq.com logoCelldex's Immuno-Oncology Pipeline Continues to Impress
www.nasdaq.com - May 26 at 4:48 PM
finance.yahoo.com logoCelldex's Immuno-Oncology Pipeline Continues to Impress
finance.yahoo.com - May 26 at 4:48 PM
fool.com logoBetter Buy: Celldex Therapeutics, Inc. vs. Agenus Inc.
www.fool.com - May 21 at 6:44 AM
nasdaq.com logoCelldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting - Nasdaq
www.nasdaq.com - May 18 at 11:13 AM
globenewswire.com logoCelldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting - GlobeNewswire (press release)
globenewswire.com - May 17 at 9:23 PM
finance.yahoo.com logoCelldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
finance.yahoo.com - May 17 at 9:23 PM
prnewswire.com logoBiotech Stocks Under Scanner -- BioCryst Pharma, Biogen, Celldex ... - PR Newswire (press release)
www.prnewswire.com - May 16 at 4:22 PM
americanbankingnews.com logoZacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Quarterly Sales of $520,000.00
www.americanbankingnews.com - May 14 at 9:15 AM
americanbankingnews.com logo-$0.27 EPS Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - May 12 at 6:20 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. to Post Q2 2017 Earnings of ($0.23) Per Share, Leerink Swann Forecasts (CLDX)
www.americanbankingnews.com - May 12 at 10:40 AM
americanbankingnews.com logoJefferies Group Weighs in on Celldex Therapeutics, Inc.'s Q2 2017 Earnings (CLDX)
www.americanbankingnews.com - May 12 at 10:40 AM
americanbankingnews.com logoShort Interest in Celldex Therapeutics, Inc. (CLDX) Expands By 7.9%
www.americanbankingnews.com - May 12 at 7:04 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - May 11 at 4:46 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. Expected to Post FY2019 Earnings of ($0.54) Per Share (CLDX)
www.americanbankingnews.com - May 11 at 3:20 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Releases Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - May 11 at 2:20 PM
nasdaq.com logoCelldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up - Nasdaq
www.nasdaq.com - May 10 at 9:30 PM
rttnews.com logoCelldex Reports Updated 2017 Guidance - Quick Facts
www.rttnews.com - May 9 at 9:22 PM
fool.com logoCelldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update
www.fool.com - May 9 at 9:22 PM
marketbeat.com logoCelldex reports 1Q loss
marketbeat.com - May 9 at 5:44 PM
globenewswire.com logoCelldex Reports First Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - May 9 at 4:20 PM
seekingalpha.com logoCelldex Therapeutics: Nobody Expects The Spanish Inquisition - Seeking Alpha
seekingalpha.com - May 9 at 4:20 PM
finance.yahoo.com logoCelldex Reports First Quarter 2017 Results
finance.yahoo.com - May 9 at 4:19 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 9 at 9:02 AM
americanbankingnews.com logoFavorable News Coverage Unlikely to Impact Celldex Therapeutics (CLDX) Stock Price
www.americanbankingnews.com - May 4 at 11:40 AM
finance.yahoo.com logoCelldex Therapeutics (CLDX) Q1 Earnings: What's in Store? - Yahoo Finance
finance.yahoo.com - May 3 at 8:23 AM
zacks.com logoCelldex Therapeutics (CLDX) Q1 Earnings: What's in Store?
www.zacks.com - May 2 at 7:49 PM
finance.yahoo.com logoCelldex Therapeutics (CLDX) Q1 Earnings: What's in Store?
finance.yahoo.com - May 2 at 7:49 PM
americanbankingnews.com logoSomewhat Critical News Coverage Very Likely to Affect Celldex Therapeutics (CLDX) Share Price
www.americanbankingnews.com - May 1 at 6:00 PM
americanbankingnews.com logoCelldex Therapeutics (CLDX) Given Daily Coverage Optimism Score of -0.10
www.americanbankingnews.com - April 28 at 2:44 PM
americanbankingnews.com logoShort Interest in Celldex Therapeutics, Inc. (CLDX) Declines By 12.4%
www.americanbankingnews.com - April 27 at 7:20 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Celldex ... - Yahoo Finance
finance.yahoo.com - April 23 at 9:36 PM
americanbankingnews.com logo Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $570,000.00
www.americanbankingnews.com - April 23 at 7:54 AM
americanbankingnews.com logoZacks: Analysts Expect Celldex Therapeutics, Inc. (CLDX) to Announce -$0.28 EPS
www.americanbankingnews.com - April 22 at 12:23 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum Pharmaceuticals
finance.yahoo.com - April 21 at 9:24 AM
nasdaq.com logoWhat's in Store for Biogen (BIIB) this Earnings Season?
www.nasdaq.com - April 20 at 9:29 PM
americanbankingnews.com logoCelldex Therapeutics (CLDX) Receiving Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 20 at 6:15 PM
nasdaq.com logoWhy Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - April 19 at 9:19 PM
finance.yahoo.com logoETFs with exposure to Celldex Therapeutics, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 4:19 PM
finance.yahoo.com logoWhy Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report?
finance.yahoo.com - April 19 at 12:52 PM
finance.yahoo.com logo3 Cancer Drug Stocks That Could Make You Rich
finance.yahoo.com - April 17 at 12:09 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 14 at 10:00 AM
americanbankingnews.com logoCelldex Therapeutics (CLDX) Receives Daily Media Sentiment Score of -0.22
www.americanbankingnews.com - April 14 at 7:54 AM
finance.yahoo.com logoETFs with exposure to Celldex Therapeutics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 4:19 PM
finance.yahoo.com logo3 Top Stocks You've Been Overlooking
finance.yahoo.com - April 7 at 9:00 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma
finance.yahoo.com - March 31 at 4:28 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) to Post FY2017 Earnings of ($1.23) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - March 23 at 9:32 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Receives "Buy" Rating from Aegis
www.americanbankingnews.com - March 23 at 8:53 AM
americanbankingnews.com logoJefferies Group LLC Cuts Celldex Therapeutics, Inc. (CLDX) Price Target to $4.00
www.americanbankingnews.com - March 21 at 7:40 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 20 at 12:07 PM
finance.yahoo.com logoCELLDEX THERAPEUTICS, INC. Financials
finance.yahoo.com - March 18 at 4:09 PM

Social

Chart

Celldex Therapeutics (CLDX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff